Gene therapy for rare brain disease sets a new pricing record at $4.25 million
FiercePharma - 20-Mar-2024Its record-breaking price raises questions about affordability and access
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
Writer at Fierce Pharma
Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and Fierce Pharma’s LinkedIn showcase pages. Before diving into pharma reporting, Fraiser worked as a writing teaching fellow and later as a full-time writing teacher in New York City.
Visit website: https://www.fiercepharma.com/person/fraiser-kansteiner-0
See also
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company.
Details last updated 08-Apr-2024
Its record-breaking price raises questions about affordability and access